152 related articles for article (PubMed ID: 1516609)
1. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.
Scavone JM; Greenblatt DJ; Goddard JE; Friedman H; Harmatz JS; Shader RI
Eur J Clin Pharmacol; 1992; 42(4):439-43. PubMed ID: 1516609
[TBL] [Abstract][Full Text] [Related]
2. Alprazolam kinetics following sublingual and oral administration.
Scavone JM; Greenblatt DJ; Shader RI
J Clin Psychopharmacol; 1987 Oct; 7(5):332-4. PubMed ID: 3680603
[TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects.
Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
J Clin Pharmacol; 1998 Jan; 38(1):14-21. PubMed ID: 9597554
[TBL] [Abstract][Full Text] [Related]
4. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.
Yasui N; Kondo T; Otani K; Furukori H; Kaneko S; Ohkubo T; Nagasaki T; Sugawara K
Psychopharmacology (Berl); 1998 Oct; 139(3):269-73. PubMed ID: 9784084
[TBL] [Abstract][Full Text] [Related]
5. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
J Clin Psychopharmacol; 2000 Jun; 20(3):338-46. PubMed ID: 10831021
[TBL] [Abstract][Full Text] [Related]
6. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.
Yasui N; Otani K; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 May; 59(5):514-9. PubMed ID: 8646822
[TBL] [Abstract][Full Text] [Related]
7. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
[TBL] [Abstract][Full Text] [Related]
8. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam.
Furukori H; Otani K; Yasui N; Kondo T; Kaneko S; Shimoyama R; Ohkubo T; Nagasaki T; Sugawara K
Neuropsychopharmacology; 1998 May; 18(5):364-9. PubMed ID: 9536449
[TBL] [Abstract][Full Text] [Related]
9. Premedication with sublingual or oral alprazolam in adults undergoing diagnostic upper gastrointestinal endoscopy.
Shavakhi A; Soleiman S; Gholamrezaei A; Khodadoostan M; Shavakhi S; Tahery A; Minakari M
Endoscopy; 2014 Aug; 46(8):633-9. PubMed ID: 24977401
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.
Smith RB; Kroboth PD; Vanderlugt JT; Phillips JP; Juhl RP
Psychopharmacology (Berl); 1984; 84(4):452-6. PubMed ID: 6152055
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
Wright CE; Sisson TL; Fleishaker JC; Antal EJ
J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic effects of a single nocturnal dose of alprazolam.
Norman TR; Burrows GD; McIntyre IM
Int Clin Psychopharmacol; 1990 Apr; 5(2):111-7. PubMed ID: 2199575
[TBL] [Abstract][Full Text] [Related]
13. Relationship between single oral dose pharmacokinetics of alprazolam and triazolam.
Otani K; Yasui N; Furukori H; Kaneko S; Tasaki H; Ohkubo T; Nagasaki T; Sugawara K; Hayashi K
Int Clin Psychopharmacol; 1997 May; 12(3):153-7. PubMed ID: 9248872
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.
Calvo G; García-Gea C; Luque A; Morte A; Dal-Ré R; Barbanoj M
J Clin Psychopharmacol; 2004 Jun; 24(3):268-76. PubMed ID: 15118480
[TBL] [Abstract][Full Text] [Related]
15. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo.
Greenblatt DJ; Harmatz JS; Dorsey C; Shader RI
Clin Pharmacol Ther; 1988 Sep; 44(3):326-34. PubMed ID: 3138056
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.
Venkatakrishnan K; Culm KE; Ehrenberg BL; Harmatz JS; Corbett KE; Fleishaker JC; Greenblatt DJ
J Clin Pharmacol; 2005 May; 45(5):529-37. PubMed ID: 15831776
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.
Park JY; Kim KA; Park PW; Lee OJ; Kang DK; Shon JH; Liu KH; Shin JG
Clin Pharmacol Ther; 2006 Jun; 79(6):590-9. PubMed ID: 16765147
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and physiologic effects of alprazolam after a single oral dose in healthy mares.
Wong DM; Davis JL; Alcott CJ; Hepworth-Warren KL; Galow-Kersh NL; Rice S; Coetzee JF
J Vet Pharmacol Ther; 2015 Jun; 38(3):301-4. PubMed ID: 25427652
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation.
Fleishaker JC; Phillips JP; Eller MG; Smith RB
J Clin Pharmacol; 1989 Jun; 29(6):543-9. PubMed ID: 2754023
[TBL] [Abstract][Full Text] [Related]
20. Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing.
Kroboth PD; McAuley JW; Smith RB
Psychopharmacology (Berl); 1990; 100(4):477-84. PubMed ID: 2320708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
